Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
Holding DE:6MK?
Track your performance easily
6MK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€89.60 - €125.60
Previous Close€96.6
Volume19.00
Average Volume (3M)2.29K
Market Cap
€247.50B
Enterprise Value€267.31B
Total Cash (Recent Filing)$14.59B
Total Debt (Recent Filing)$38.13B
Price to Earnings (P/E)22.0
Beta0.16
Next Earnings
Feb 04, 2025EPS Estimate
€1.76Next Dividend Ex-Date
Dec 16, 2024Dividend Yield3.1%
Share Statistics
EPS (TTM)4.40
Shares Outstanding2,529,635,645
10 Day Avg. Volume1,816
30 Day Avg. Volume2,289
Standard Deviation0.06
R-Squared0.05
Alpha0.00803
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)6.60
P/FCF Ratio7.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.23
Enterprise Value/Gross Profit6.08
Enterprise Value/Ebitda14.14
Forecast
1Y Price Target
€127.17Price Target Upside31.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsZENITH trial has been stopped early due to overwhelming efficacy of sotatercept in functional class III/IV PAH patients.
Product PerformanceWinrevair continued to see strong growth, reporting $149M for the quarter (+16% vs. consensus).
Regulatory DevelopmentsMerck plans to submit ZENITH results to FDA for additional labeling considerations, which could help further accelerate an already impressive launch, providing incremental revenue and share upside.
Bears Say
EarningsGardasil remains a concern with revenues -10% vs. consensus, likely continued to be impacted by problems in China.
Market CompetitionA local competitor is poised to launch their own 9-valent option in China next year.
Product PerformanceCompetitor Summit Therapeutics presented detailed data from their HARMONi-2 Phase 3 trial in PD-L1 positive NSCLC showing a statistically significant median PFS benefit compared to MRK's Keytruda.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.04% Insiders
21.57% Mutual Funds
15.55% Other Institutional Investors
42.16% Public Companies and
Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €89.60 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 04, 2025 which is in 69 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 31, 2024. The company reported €1.497 earnings per share for the quarter, beating the consensus estimate of €1.415 by €0.082.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.764 which represents an annual dividend yield of 3.1%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is €1.76.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,529,635,700 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.497 in its last earnings report, beating expectations of €1.415. Following the earnings report the stock price went down -1.569%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€127.17 (31.65% Upside)
€127.17 (31.65% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 86%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.40%
12-Months-Change
Fundamentals
Return on Equity
28.33%
Trailing 12-Months
Asset Growth
10.12%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
6MK Company Deck
---
6MK Earnings Call
Q3 2024
0:00 / 0:00
---
6MK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€127.17
▲(31.65% Upside)
Technical Analysis
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
39/53 ratings generated profit
1 Year Average Return
+12.88%
reiterated a buy rating 10 months ago
Copying Mara Goldstein's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.88% per trade.
---